Menu
Recruiting NCT07304518

Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults

Phase II Interventional Migraine

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: PRT-064040 nasal spray, Placebo.
Who it may be relevant to
Registry conditions: Migraine. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase II Trial of PRT-064040 Nasal Spray for the Acute Treatment of Migraine

Overview

The purpose of this study is to learn about the efficacy and safety of PRT-064040 Nasal Spray versus placebo in the acute treatment of moderate or severe migraine.

Interventions

  • Drug PRT-064040 nasal spray
    A single dose of PRT-064040 nasal spray
  • Drug Placebo
    A single dose of placebo matched to PRT-064040 nasal spray

Primary outcome measures

  • Percentage of Participants With Freedom From Pain at 2 Hours Post-dose [Time frame: 2 hours post-dose]
  • Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose [Time frame: 2 hours post-dose]
Secondary outcome measures (12)
  • Percentage of Participants With Pain Relief at 15 Minutes Post-dose [Time frame: 15 minutes post-dose]
  • Percentage of Participants With Pain Relief at 30 Minutes Post-dose [Time frame: 30 minutes post-dose]
  • Percentage of Participants With Pain Relief at 60 Minutes Post-dose [Time frame: 60 minutes post-dose]
  • Percentage of Participants With Pain Relief at 2 Hours Post-dose [Time frame: 2 hours post-dose]
  • Percentage of Participants Who Were Able to Function Normally at 2 Hours Post-dose [Time frame: 2 hours post-dose]
  • Percentage of Participants With Sustained Pain Relief From 2 Hours to 24 Post-dose [Time frame: From 2 to 24 hours post-dose]
  • Percentage of Participants With Sustained Pain Relief From 2 Hours to 48 Post-dose [Time frame: From 2 to 48 hours post-dose]
  • Percentage of Participants Who Were Able to Function Normally at 30 Minutes Post-dose [Time frame: 30 minutes post-dose]
  • Percentage of Participants Who Were Able to Function Normally at 60 Minutes Post-dose [Time frame: 60 minutes post-dose]
  • Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose [Time frame: 2 hours post-dose]
  • Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose [Time frame: 2 hours post-dose]
  • Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose [Time frame: 2 hours post-dose]

Eligibility criteria

Inclusion criteria

Inclusion criteria

  • Male and female participants aged 18-75 years (inclusive);
  • BMI < 35 kg/m²;
  • Participant has at least 1-year history of migraines (with or without aura), consistent with a diagnosis according to the International Classification of Headache Disorder, 3rd Edition;
  • Age at first migraine onset < 50 years;
  • Migraine attacks, on average, lasting about 4-72 hours if untreated or treatment-resistant;
  • 2-8 attacks of moderate to severe intensity per month within the last 3 months；
  • Less than 15 days with headache (migraine or non-migraine) per month within the last 3 months；
  • Participants on prophylactic migraine medication are permitted to remain on therapy provided they have been on a stable dose for at least 3 months prior to screening visit and the dose is not expected to change until the EOT visit;
  • Patients diagnosed with chronic migraine who, owing to stable preventive therapy, have < 15 headache days and 2-8 attacks of moderate to severe intensity per month in the 3 months before screening, and who meet all other entry criteria, may be enrolled;
  • Able to comprehend and complete study questionnaires with electronic patient-reported outcome (e-PRO) application.

Exclusion criteria

Exclusion criteria

  • Participant with history of migraine with brainstem aura, retinal migraine, or hemiplegic migraine.
  • Participant with evidence of poorly controlled, unstable, or recently diagnosed cardiovascular or cardiometabolic disease, or prior history thereof, including:
  • Ischemic heart disease, coronary vasospasm, or cerebral ischemia diagnosed within 6 months before screening;
  • Previous stroke, transient ischemic attack, myocardial infarction, acute coronary syndrome, cardiac surgery, or percutaneous coronary intervention;
  • Abnormal 12-lead ECG at screening;
  • Poorly controlled diabetes mellitus or hypertension;
  • Poorly controlled or severe peripheral vascular disease.
  • Participant with any nasal structural abnormality, mucosal lesion, or disorder that could interfere with intranasal drug absorption.
  • Participant with dysgeusia, hypogeusia, or related taste disorders.
  • Participant with acute or chronic pain syndromes, or any other pain that in the investigator's opinion could confound study assessments.
  • Participant with history of regular use of ergotamine or triptans ≥ 10 days per month for ≥ 3 months; or regular use of non-narcotic analgesics (e.g., acetaminophen, NSAIDs, gabapentin) ≥ 15 days per month for ≥ 3 months.
  • Clinically relevant abnormal findings in hepatitis B surface antigen, hepatitis C antibody, Treponema pallidum antibody, or HIV antibody tests at screening.
  • Participant with history of alcohol or drug abuse within 1 year before screening, or positive urine drug screen at screening.
  • Pregnant or lactating women, or positive pregnancy test at screening.
  • Participant with known hypersensitivity to the investigational product or any of its excipients, or history of significant allergic reactions.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

China · 1 center
  • The First Medical Center of PLA General Hospital — Beijing

Identifiers

NCT: NCT07304518 · BT-PRT-064-201

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗